Phase 3Completed

Testosterone, Metformin, or Both, for Hypogonadism in Obese Males

Randomized, Double-blind, Parallel, Placebo-controlled, Clinical Trial to Assess the Efficacy of Testosterone, Metformin, or Both, for the Treatment of Obesity-induced Male Hypogonadism

Sponsor
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (Academic or other)
Enrollment
107 enrolled
Conditions
Hypogonadism; Obesity
Interventions
Placebo; Metformin; Testosterone Undecanoate; Metformin + Testosterone Undecanoate
Ages
adults
Registry
NCT02514629

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to examine the effects of metformin, testosterone, or both, in males with obesity-related hypogonadism. This study will evaluate changes in insulin resistance, weight loss, body composition, testosterone levels,quality of life and erectile dysfunction. Obese men will receive diet and physical activity counselling, and be randomised to either testosterone, metformin, a combination of both or placebo

Primary outcomes

  • Change in Insulin Resistance

History

  1. Last registry update

  2. Primary completion

  3. Registered

  4. Started

Papers citing this trial